Similar articles

• Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).

  de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P; European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. de Reijke TM, et al. J Urol. 2005 Feb;173(2):405-9. doi: 10.1097/01.ju.0000150425.09317.67. J Urol. 2005. PMID: 15643181 Clinical Trial.
• Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.

  Ooi WL, Stockler M, Hayne D. Ooi WL, et al. Eur Urol. 2011 Jul;60(1):e1; author reply e2-3. doi: 10.1016/j.eururo.2011.03.050. Epub 2011 Apr 5. Eur Urol. 2011. PMID: 21489685 No abstract available.
• Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.

  Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA. Ali-El-Dein B, et al. J Urol. 1999 Aug;162(2):339-42. J Urol. 1999. PMID: 10411034 Clinical Trial.
• [Management of Ta, T1, and in situ bladder carcinoma: what is new?].

  Irani J. Irani J. Prog Urol. 2008 May;18 Suppl 5:S94-8. doi: 10.1016/S1166-7087(08)72484-9. Prog Urol. 2008. PMID: 18585634 Review. French.
• The role of adriamycin and epirubicin in superficial bladder cancer and carcinoma in situ.

  da Silva FC. da Silva FC. Prog Clin Biol Res. 1989;303:401-10. Prog Clin Biol Res. 1989. PMID: 2675001 Review. No abstract available.